Markets
News
Analysis
User
24/7
Economic Calendar
Education
Data
- Names
- Latest
- Prev
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
A:--
F: --
A:--
F: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
No matching data
Latest Views
Latest Views
Trending Topics
To quickly learn market dynamics and follow market focuses in 15 min.
In the world of mankind, there will not be a statement without any position, nor a remark without any purpose.
Inflation, exchange rates, and the economy shape the policy decisions of central banks; the attitudes and words of central bank officials also influence the actions of market traders.
Money makes the world go round and currency is a permanent commodity. The forex market is full of surprises and expectations.
Top Columnists
Enjoy exciting activities, right here at FastBull.
The latest breaking news and the global financial events.
I have 5 years of experience in financial analysis, especially in aspects of macro developments and medium and long-term trend judgment. My focus is maily on the developments of the Middle East, emerging markets, coal, wheat and other agricultural products.
BeingTrader chief Trading Coach & Speaker, 8+ years of experience in the forex market trading mainly XAUUSD, EUR/USD, GBP/USD, USD/JPY, and Crude Oil. A confident trader and analyst who aims to explore various opportunities and guide investors in the market. As an analyst I am looking to enhance the trader’s experience by supporting them with sufficient data and signals.
Latest Update
Risk Warning on Trading HK Stocks
Despite Hong Kong's robust legal and regulatory framework, its stock market still faces unique risks and challenges, such as currency fluctuations due to the Hong Kong dollar's peg to the US dollar and the impact of mainland China's policy changes and economic conditions on Hong Kong stocks.
HK Stock Trading Fees and Taxation
Trading costs in the Hong Kong stock market include transaction fees, stamp duty, settlement charges, and currency conversion fees for foreign investors. Additionally, taxes may apply based on local regulations.
HK Non-Essential Consumer Goods Industry
The Hong Kong stock market encompasses non-essential consumption sectors like automotive, education, tourism, catering, and apparel. Of the 643 listed companies, 35% are mainland Chinese, making up 65% of the total market capitalization. Thus, it's heavily influenced by the Chinese economy.
HK Real Estate Industry
In recent years, the real estate and construction sector's share in the Hong Kong stock index has notably decreased. Nevertheless, as of 2022, it retains around 10% market share, covering real estate development, construction engineering, investment, and property management.
Hongkong, China
Ho Chi Minh, Vietnam
Dubai, UAE
Lagos, Nigeria
Cairo, Egypt
White Label
Data API
Web Plug-ins
Affiliate Program
View All
No data
Not Logged In
Log in to access more features
FastBull Membership
Not yet
Purchase
Log In
Sign Up
Hongkong, China
Ho Chi Minh, Vietnam
Dubai, UAE
Lagos, Nigeria
Cairo, Egypt
White Label
Data API
Web Plug-ins
Affiliate Program
The Dubai branch & Saudi entity of BD (Becton, Dickinson and Company) , a leading global medical technology company, today reaffirmed its commitment to patient safety and sepsis management in recognition of World Sepsis Day on September 13 and World Patient Safety Day on September 17.
This year’s theme for World Patient Safety Day, “Improving Diagnosis for Patient Safety,” aligns perfectly with BD’s ongoing efforts to enhance diagnostic accuracy and reduce adverse events in healthcare settings. Through its Signature ProgrammesTM, BD continues to innovate and deliver solutions that aim to prevent errors and improve patient outcomes across the globe.
Sepsis is a critical public health issue affecting 49 million people worldwide annually, resulting in 11 million deaths. Advancements in medication management, infection prevention, and diagnostic accuracy are pivotal in addressing these global health challenges[1]. By improving early diagnosis and fostering appropriate treatment, BD aims to significantly reduce the burden of sepsis and other healthcare-associated infections (HAIs).
“As a company committed to advancing the world of health, BD recognizes the importance of patient safety as a fundamental component of healthcare delivery,” said Maher Elhassan, Vice President and General Manager of BD Middle East, North Africa, and Turkey. “On these significant days, we reiterate our dedication to collaborating with healthcare professionals to deliver safer, more efficient, and sustainable healthcare solutions. Patient Safety is a core pillar of our Signature ProgrammesTM designed to protect both patients and healthcare workers by reducing medication errors, preventing HAIs, and improving overall healthcare efficiency.”
BD Signature ProgrammesTM focus on three critical areas: Patient Safety, Healthcare Workers Wellbeing, and Healthcare Efficiency. These programs are designed to minimize errors, protect healthcare workers, reduce waste, and enhance outcomes, directly aligning with global health priorities.
According to World Health Organization, around 1 in 10 patients is harmed during healthcare. Above 50% of harm (1 in every 20 patients) is preventable; half of them is attributed to medications[2]. BD’s efforts in automation, diagnostic accuracy, and connected medication management play a crucial role in minimizing these risks. Through innovative technologies and comprehensive education and training programs, the company supports healthcare systems worldwide in creating safer, more reliable environments for both patients and providers.
As BD continues to lead in medical innovation, it remains steadfast in its efforts to empower healthcare providers and improve patient outcomes. On World Sepsis Day and World Patient Safety Day, the company calls upon healthcare professionals and organizations worldwide to join in advancing the shared goal of safer healthcare for all.
This is intended for Healthcare Professionals only.
About BD:
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson.
For more information (Press only):
Rania.Raad@bd.com
BD@proglobal.ae
[1] PDF) the global burden of sepsis: Barriers and potential solutions. Sepsis Alliance Suspect Sepsis Save Lives. 2020. Accessed September 13, 2024. https://www.researchgate.net/publication/327833100_The_global_burden_of_sepsis_Barriers_and_potential_solutions.
[2] Patient safety. World Health Organization. 2023. Accessed September 13, 2024. https://www.who.int/news-room/fact-sheets/detail/patient-safety.
Send us your press releases to pressrelease.zawya@lseg.comDisclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
Kuwait City, Kuwait – BD (Becton, Dickinson and Company) , one of the leading global medical technology companies, in collaboration with Advanced Technology Company (ATC) in Kuwait, hosted the inaugural Kuwait Pharmacy Automation Conference. Held at the Radisson Blu hotel, the event underscored BD's commitment to revolutionizing medication management processes through the integration of advanced automation technologies.
Maher Elhassan, Vice President and General Manager of BD Middle East, North Africa, and Turkey, said, “the Kuwait Pharmacy Conference offers a unique opportunity to engage with industry experts and leaders to explore best practices in automation and its pivotal role in advancing healthcare outcomes. Our initiative in collaboration with partners like ATC reflects a shared commitment to fostering a resilient, sustainable, and efficient healthcare ecosystem. By leveraging BD’s cutting-edge technology, we aim to ensure that Kuwaiti healthcare facilities are equipped to deliver the highest standard of patient care and safety.
With 68% of medication errors occurring during administration[1], there is a clear need for greater medication management consistency to reduce risk and enhance patient safety. Moreover, globally, the annual cost associated with medication errors has been estimated at $42 billion USD. Through its Signature ProgrammesTM, BD continues to focus on three critical areas: patient safety, healthcare worker safety, and healthcare efficiency. These programs, which include pharmacy automation solutions, are designed to minimize errors, reduce waste, and improve outcomes. This aligns seamlessly with Kuwait’s healthcare priorities of enhancing service quality, implementing sustainable practices, and fostering human capital development.
“We are thrilled to collaborate with BD in showcasing the importance of automation in pharmacy and medication management,” said Ghassan Mamlouk, CEO at ATC. “This initiative demonstrates our shared dedication to empowering healthcare professionals with the latest technological advancements. Together, we are paving the way for safer, more efficient, and patient-centred healthcare practices in Kuwait.”
This is intended for Healthcare Professionals only.
About BD:
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson.
For more information (Press only):
Rania.Raad@bd.com
BD@proglobal.ae
[1] 1. C—0651. California Hospital Patient Safety Organization. Patient Safety News. 2012, October. 4(9)
Send us your press releases to pressrelease.zawya@lseg.comDisclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
Dividend Aristocrats are some of the most sought-after companies for long-term income investors. Indeed, increasing dividends for over 25 years while maintaining profitability, stability, and market leadership makes attractive investments for those aiming to bolster their retirement funds.
However, not all Dividend Aristocrats are created equal. Some offer higher yields, while some offer higher increases. I'll be looking at the latter today, gauging Dividend Aristocrats with strong positive Wall Street followings and enough financial overhead to boost their dividend payments in the next few years. Let’s get to it.
How I Came Up With The Following Stocks
To get my list, I came up with the following combination of filters:
After running the scan, I got five results. I arranged the list from those with the lowest to highest dividend payout ratio- this way, I'll be able to see who has the most money left to potentially use for dividends. Now I have I my list of dividend aristocrats with the lowest dividend payout ratio, and I've chosen the top three for this article.
There’s no doubt that S&P Global deserves a spot on this list. The market intelligence analytics and credit rating agency is behind the massive S&P 500 Index, which tracks 500 of the biggest companies in the United States and is considered a barometer for overall market conditions.
Long-term investors interested in S&P Global can find a lot of attractive qualities in the company. SPGI stock has risen by over 500% in the last ten years, and yet analysts still see massive potential growth, rating it a strong buy with an average score of 4.83 out of 5.
Its Q2 2024 report leaves no doubt that analysts have ample reason to give it such high scores. Revenue was up a modest 14.45% year-over-year (YOY) from $3.10 billion to $3.55 billion. Also, by keeping expenses in line with last year, the company reached $1.08 billion in net income or $3.23 per share—a massive 102% EPS increase YOY.
As for dividends, SPGI pays some of the lowest yields on the Dividend Aristocrats list. At $3.64 annually, that translates to a paltry 0.007% yield. However, the company is still a viable long-term income stock as its payout ratio is just 25.07%. That means it has just under 75% of its net income to use for other things, like growing its dividend!
Becton Dickinson and Company is a global medical technology company that manufactures and sells medical devices, laboratory equipment, and diagnostic products. The company's offerings span drug delivery systems, diagnostic solutions, and surgical instruments.
The company’s Q3 2024 report was relatively flat YOY, with revenue reaching almost $5 billion, up modestly from last year’s $4.88 billion, while earnings grew from $1.37 to $1.68 per share. The bulk of its revenue came from its Medical segment, which grew significantly from $588 million to $753 million.
Meanwhile, BDX stock pays 95 cents per share for quarterly dividends, translating to a $3.80 annual rate and a 1.61% yield, and maintains a low 29.26% payout ratio. This low payout ratio will allow it to continue growing its dividend for years to come. Oh, and it also helps that the company has a 4.59 average score from 17 analysts, making it a relatively safe and attractive addition to your long-term income portfolio.
Retail giant Walmart is currently on a historic bull run that is almost comparable to its explosive growth in the late 1990s. WMT stock is currently up 51.59% YTD, trading within a hair of its recent $79.90 all-time high. With the way things are going, the stock will likely break through soon.
Thirty-two analysts rate WMT a strong buy, giving it a 4.69 average score, and a high target price of $90 (some even predict it will trade above $100 before the year ends), indicating confidence that the stock has more room for growth.
This may surprise those who reviewed Walmart’s most recent financials, which reported modest revenue growth from $161.6 billion to $169.3 billion, yet earnings dipped by more than 40%.
Indeed, Walmart is seeing an increase in shoppers across its stores, with a growing number of them from high-income households. Additionally, the company’s majority-owned fintech One Finance’s offer for buy now, pay later opportunities across its 4,606 U.S. stores is attracting more buyers.
WMT stock pays 84 cents per share in annual dividends, translating to a 1.05% yield, and has a 33.29% payout ratio. That low payout ratio, I have no doubt Walmart can double their dividend over time. Combined with its increasing market share and impressive prospects, Walmart is in an excellent position to increase its dividends over the long haul, making it a viable long-term investment.
Final Thoughts
Dividend investing is not all about yields. You also need to keep an eye on dividend growth—and if the company in question is in a position to increase its dividends over the long term. These three present great buying opportunities, but remember, things can change, so monitor your positions and keep an ear out for any new developments.
On the date of publication, Rick Orford did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
The past month has been quite encouraging for Medtronic MDT investors. Solid first-quarter fiscal 2025 organic growth performance and several strategic initiatives to revamp the bottom line, including the COGS cost-out programs, while maintaining pricing and maximizing efficiencies, seem to have boosted market sentiment.
Added to this, growing optimism surrounding the Fed’s approach toward an imminent rate cut in September acts as a strong impetus in driving the stock price. All these have nullified the ongoing impact of global geopolitical pressure, primarily disruptions around the Red Sea, which have significantly increased freight costs and shipping lead times, spelling trouble for Medtronic and other medical device players.
Over the past month, shares of Medtronic have gained more than 12%, steering ahead of the benchmark’s 2% growth, the broader industry’s 8.8% rise and the sector’s 3.7% growth. The company also strongly outperformed its key rivals like Boston Scientific BSX, Abbott ABT and Becton, Dickinson and Company or BD BDX over the past 30 days.
One-Month Price Performance of MDT
MDT Gets Golden Crossover Support
MDT stock has traded significantly above its 200-day moving average since July 26, 2024. The stock witnessed a golden crossover on Sept. 9, 2024, and since then, the 50-day moving average has been ahead of the 200-day moving average. This can be a piece of good news for MDT investors, signaling “support” for a continued uptrend.
MDT Above the 50 and 200-day SMA
Factors Driving Medtronic Shares
Medtronic is strategically expanding its global presence to address the unmet demand for advanced medical devices. A series of strategic product launches are particularly helping the company to enjoy MedTech's most attractive markets like AFib, Structural Heart, robotics, neuromodulation, hypertension and diabetes. AI application across the portfolio has further enhanced market demand for MDT products.
Medtronic's Dividend Track Record
While the Cardiovascular segment is seeing strong growth within the Micra leadless pacemaker franchise and Aurora line of defibrillation solutions, in MedSurg, Medtronic is scaling the production of Hugo RAS.
Innovations and market expansion efforts are helping it offset the impact of supply disruptions and cost escalations. Within Neuromodulation, currently, the company is fast gaining traction, primarily banking on Brain Modulation, which is benefiting from the continued launch of Percept RC with Brain Sense technology — the only complete sensing-enabled DBS system available in the market. Further, the Inceptiv platform has proved to be a game changer in chronic pain therapy.
Diabetes is another area of significant growth for MDT. In the United States, the company is benefiting from the ongoing rollout of the MiniMed 780G system. The company is also hopeful about high market acceptance following the recent full market release of the Simplera Sync sensor in the European market.
Medtronic’s strong liquidity position should allow it to meet its near-term debt obligations. Medtronic apparently looks quite burdened by debt, with total debt (including the current portion) of $27.87 billion as of July 26, 2024. The company’s cash and cash equivalents were $7.8 billion at the end of the first quarter of fiscal 2025. Although the quarter’s total debt was much higher than the corresponding cash and cash equivalent level, the short-term payable debt of $1.55 billion remains lower than the short-term cash level. The company’s times interest earned ratio too is at an impressive level of 7.7 indicating that Medtronic is well capable of paying the interest on its business debts on time.
Further, Medtronic, as a popular dividend-paying stock, managed to increase its quarterly dividend for the 47th straight quarter this May. Effective May 22, 2024, Medtronic's board of directors approved an increase in its cash dividend for the first quarter of fiscal year 2025, raising the quarterly amount to $0.70 per ordinary share. This represents an annual amount of $2.80 per ordinary share. The current payout ratio stands at 52.9%. This compares with the payout rate of the industry, which stands at a lower level of 36.8%.
All these factors support our bullish stance on the stock.
Cheap Valuation
Meanwhile, if we look at the value components, MDT has a Value Score of B at present.
This is evident from the Price/Earnings ratio. MDT shares currently trade at 16.30X forward earnings, well off its five-year high of 30.08X and below the median of 17.36X. The stock is also trading significantly below the industry’s 21.88X.
The company is also trading at a significant discount to its peers like BSX, whose current P/E is 31.76X, and ABT, whose current P/E is 23.49X. This suggests that investors may be paying a lower price relative to the company's expected earnings growth.
Two Major Stumbling Blocks for Medtronic
Sino-U.S. Trade Complications to Mar Growth: Medtronic, which earns a significant percentage of revenues from China, is currently grappling with the growing Sino-U.S. trade complications. The 2024 National Trade Estimate report depicted severe concern around this scenario and outlined the overwhelming impact of Chinese volume-based procurement (VBP) and the Made in China 2025 industrial plan on U.S. medical device businesses.
Medtronic, which records approximately 7% of its operational revenues from China (as of fiscal 2024), might face a compromised trade situation in the ongoing fiscal if the trade tension between these two countries does not get resolved any time soon.
Margin Pressure: Like its peers, Medtronic is currently affected by the industry-wide increase in costs and expenses stemming from geopolitical concerns. Although inflation stabilized a bit during the fiscal first quarter, it is still higher than the historical trend. The continued increase in raw material and labor costs and oil price volatility are denting the company’s profit. Further, a rising interest rate leading to increasing borrowing costs is concerning. In the first quarter of fiscal 2025, gross margin contracted 76 basis points to 65.1% on a 5.1% rise in the cost of revenues. Further, selling, general and administrative expenses rose 1.6% year over year. Adjusted operating margin contracted 25 bps year over year to 23%.
Our Take: Hold MDT Stock for Now
Despite the company’s several recent upsides and dividend pay-out trend outperforming the industry standard, the ongoing hiccups in the form of international trade challenges and supply chain issues are limiting this Zacks Rank #3 (Hold) stock’s near-term gains. While current shareholders should hold their positions, new investors should wait for the stock to retract some of its recent gains, providing a better entry point.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks Investment Research
Becton, Dickinson, and Company , headquartered in Franklin Lakes, New Jersey, is a global medical technology company specializing in developing and manufacturing innovative medical devices, laboratory equipment, and diagnostic products. With a market cap of $67.24 billion, BDX is a major player in the healthcare industry, renowned for its extensive portfolio of products that enhance medication management, infection prevention, and diagnostic accuracy.
Companies valued at $10 billion or more are typically classified as "large-cap stocks," and Becton, Dickinson, and Company comfortably fit this category. BDX has established a strong market presence driven by its broad portfolio of medical devices, diagnostic products, and life sciences solutions, as well as its commitment to advancing healthcare and improving patient outcomes worldwide.
BDX shares are trading 12% below their 52-week high of $269.52, which they hit on Oct. 10. BDX has declined 1.4% over the past three months, underperforming the broader Nasdaq Composite ($NASX), which has gained 1.5% over the same time frame.
In the longer term, BDX is up 2.7% on a YTD basis, and the shares have gained 11.1% over the past 52 weeks. In comparison, the Nasdaq has gained 12.5% in 2024 and rallied 22.7% over the past year.
To confirm its recent bearish trend, BDX has been trading below its 200-day moving average since early October 2023. However, it's trading above the 50-day moving average since mid-July.
On Sep. 5, Becton, Dickinson, and Company completed its $4.2 billion acquisition of Edwards Lifesciences' Critical Care product group, strengthening its portfolio with advanced AI-driven patient monitoring technologies.
On Aug. 1, BDX shares dropped 2.1% after announcing its Q3 earnings report. It reported an adjusted EPS of $3.50 and total revenue of $14.7 billion, up 18.2% and 3.2% year over year, respectively. The company also updated GAAP revenue growth guidance to approximately 3.7%, with organic revenue growth expected between 5% and 5.3%.
Highlighting the contrast in performance, BDX's competitor, Baxter International Inc. , has significantly underperformed BDX. BAX has gained 1.5% on a YTD basis.
Analysts are optimistic about BDX's prospects despite the weak price performance. The stock has a consensus rating of "Strong Buy" from 17 analysts in coverage. The mean price target of $275.29 reflects a 16% premium over current levels.
On the date of publication, Rashmi Kumari did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.
It also includes access to the Zacks Style Scores.
What are the Zacks Style Scores?
The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.
Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value Score
Finding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.
Growth Score
While good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.
Momentum Score
Momentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.
VGM Score
If you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank
A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.
It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +25.41% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.
That's where the Style Scores come in.
To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.
Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Becton Dickinson (BDX)
Based in Franklin Lakes, NJ, Becton, Dickinson and Company, commonly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents.
BDX is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.
It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 18.11; value investors should take notice.
10 analysts revised their earnings estimate higher in the last 60 days for fiscal 2024, while the Zacks Consensus Estimate has increased $0.06 to $13.10 per share. BDX also boasts an average earnings surprise of 6.2%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, BDX should be on investors' short list.
Zacks Investment Research
White Label
Data API
Web Plug-ins
Poster Maker
Affiliate Program
The risk of loss in trading financial instruments such as stocks, FX, commodities, futures, bonds, ETFs and crypto can be substantial. You may sustain a total loss of the funds that you deposit with your broker. Therefore, you should carefully consider whether such trading is suitable for you in light of your circumstances and financial resources.
No decision to invest should be made without thoroughly conducting due diligence by yourself or consulting with your financial advisors. Our web content might not suit you since we don't know your financial conditions and investment needs. Our financial information might have latency or contain inaccuracy, so you should be fully responsible for any of your trading and investment decisions. The company will not be responsible for your capital loss.
Without getting permission from the website, you are not allowed to copy the website's graphics, texts, or trademarks. Intellectual property rights in the content or data incorporated into this website belong to its providers and exchange merchants.